论文部分内容阅读
目的探讨术前TC方案新辅助化疗Ⅰ_(B2)～Ⅱ_(A2)期宫颈癌的近期疗效。方法选择Ⅰ_(B2)～Ⅱ_(A2)期拟手术治疗的宫颈癌患者32例,术前采用2个疗程的TC方案静脉化疗,观察近期的疗效。结果临床近期有效率达87.5%,其中8例完全缓解。手术切除率达100%。化疗毒副反应小。术前TC方案新辅助化疗可提高手术切净率和症状改善,化疗后肿瘤直径较化疗前有不同程度的缩小,差异有显著意义(P<0.05)。结论宫颈癌TC方案新辅助化疗是安全有效的。经过术前新辅助化疗可提高宫颈癌的近期疗效,成为治疗该病的一种新手段,具有重要的临床意义。
Objective To investigate the short-term curative effect of preoperative TC regimen neoadjuvant chemotherapy for stage Ⅰ B2 (B2) cervical cancer. Methods Thirty-two patients with cervical cancer who underwent surgical treatment from stage Ⅰ B2 to stage A2 A2 were treated with 2 courses of TC chemotherapy before operation, and the curative effect was observed. Results The clinical effective rate was 87.5%, of which 8 patients were completely relieved. Surgical resection rate of 100%. Chemotherapy toxicity is small. Neoadjuvant chemotherapy with preoperative TC regimen can improve the rate of surgical resection and the improvement of symptoms. The diameter of tumor after chemotherapy is reduced to some extent compared with that before chemotherapy, and the difference is significant (P <0.05). Conclusion Cervical cancer TC regimen neoadjuvant chemotherapy is safe and effective. After preoperative neoadjuvant chemotherapy can improve the short-term effect of cervical cancer has become a new means of treatment of the disease, has important clinical significance.